0HTG.LSE Cardinal Health Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 0.04%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is 0HTG.LSE undervalued?
Graham numberThe Graham number of Cardinal Health Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cardinal Health Inc. fundamental analysis
No fundamental analysis for Cardinal Health Inc. yet.
Cardinal Health Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cardinal Health Inc.
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company offers customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It distributes branded and generic pharmaceutical, specialty p…
Full company profileCardinal Health Inc. financial statements
Cardinal Health Inc. annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 130B | 137B | 146B | 153B | 162B | 181B | 227B | 227B | 223B | 254B |
| Gross Profit | 6.15B | 6.61B | 6.30B | 6.35B | 6.36B | 6.23B | 7.41B | 7.41B | 7.86B | 9.40B |
| Operating Income | 2.49B | 2.54B | 1.82B | 1.78B | 1.82B | 1.67B | 1.24B | 1.24B | 2.47B | 3.26B |
| EBITDA | 3.01B | 3.02B | 2.73B | 2.69B | 1.31B | 126M | 1.24B | 2.86B | 3.10B | 4.22B |
| Net Income | 1.29B | 256M | 1.36B | -3.70B | 611M | -933M | 852M | 852M | 1.56B | 1.71B |
| EPS | 4.03 | 0.81 | 4.53 | -13 | 2.08 | -3.34 | 3.45 | 3.45 | 6.45 | 7.23 |
| Balance Sheet | ||||||||||
| Total Assets | 40.1B | 40.0B | 41.0B | 40.8B | 44.5B | 43.9B | - | 45.1B | 53.1B | 57.3B |
| Total Liabilities | 33.2B | 33.9B | 34.6B | 39.0B | 42.7B | 44.6B | - | 48.3B | 55.8B | 60.0B |
| Shareholders' Equity | 6.81B | 6.06B | 6.33B | 1.79B | 1.79B | -709M | - | -3.21B | -2.78B | -2.88B |
| Cash & Short-term Investments | 6.88B | 1.76B | 2.53B | 2.77B | 3.41B | 4.72B | - | 5.33B | 3.87B | 4.86B |
| Total Debt | 10.4B | 9.01B | 8.03B | 7.22B | 6.72B | 5.81B | - | 5.70B | 9.35B | 9.95B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 1.18B | 2.77B | 2.72B | 1.96B | 2.43B | 3.12B | 3.76B | 3.76B | 2.40B | 5.17B |
| Capital Expenditure | 387M | 384M | 328M | 375M | 400M | 387M | 511M | 511M | 547M | 649M |
| Free Cash Flow | 797M | 2.38B | 2.39B | 1.59B | 2.03B | 2.74B | 3.25B | 3.25B | 1.85B | 4.53B |
| Ratios | ||||||||||
| ROE | 18.9% | 4.2% | 21.5% | -206.6% | 34.1% | - | - | - | - | - |
| ROA | 3.2% | 0.6% | 3.3% | -9.1% | 1.4% | -2.1% | - | 1.9% | 2.9% | 3.0% |
| Net Profit Margin | 1.0% | 0.2% | 0.9% | -2.4% | 0.4% | -0.5% | 0.4% | 0.4% | 0.7% | 0.7% |
| Debt to Equity | 1.53x | 1.49x | 1.27x | 4.04x | 3.75x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cardinal Health Inc. dividends
- Dividend yield
- 0.04%
- Forward dividend
- -
- Payout ratio
- 28.6%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | 491M | 2.07 | 28.6% |
| 2025 | USD 494M | 2.04 | 31.6% |
| 2024 | USD 499M | 2.02 | 58.6% |
| 2023 | 499M | 2.02 | 58.6% |
| 2022 | USD 559M | 2.00 | - |
| 2021 | USD 573M | 1.95 | 93.8% |
| 2020 | USD 569M | 1.94 | - |
| 2019 | USD 577M | 1.92 | 42.3% |
| 2018 | USD 581M | 1.84 | 227.0% |
| 2017 | USD 577M | 1.80 | 44.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Cardinal Health Inc.
- Insiders 0.28%
- Institutions 91.45%
- Public & others 8.27%
- Free float 232M
Cardinal Health Inc. company profile
- Company name
- Cardinal Health Inc.
- Ticker
- 0HTG.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 58,788
- Fiscal year end
- June
- Address
- 7000 Cardinal Place, Dublin, OH, United States, 43017
- Phone
- 614 757 5000
- Website
- cardinalhealth.com
About Cardinal Health Inc.
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company offers customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The company also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; pharmacy management services to hospitals; operates pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products. In addition, it manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compression, incontinence, nutritional delivery, and wound care products; single-use surgical drapes, gowns, and apparel products; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. Further, the company distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile and non-sterile procedure kits. Additionally, it manufactures, prepares, and delivers radiopharmaceuticals; and optimizes direct shipments through integrated technology solutions. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Cardinal Health Inc. management
10- Mr. Jason M. HollarCEO & Director · born 1973
- Mr. Aaron E. Alt J.D.Chief Financial Officer · born 1972
- Ms. Jessica L. MayerChief Legal & Compliance Officer · born 1969
- Mr. Stephen M. MasonChief Executive Officer of GMPD segment · born 1971
- Ms. Deborah L. WeitzmanChief Executive Officer of Pharmaceutical & Specialty Solutions Segment · born 1965
- Ms. Mary C. SchererSenior VP & Chief Accounting Officer
- Mr. David FrostVice President of Investor Relations
- Ms. Valerie Christine PitteroffChief Human Resources Officer · born 1971
- Mr. Craig CowmanPresident of Biopharma Solutions & Strategic Sourcing
- Mr. Ben BrinkerPresident of Global Operations & Supply Chain